Soon Hin How

4.7k total citations
46 papers, 396 citations indexed

About

Soon Hin How is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, Soon Hin How has authored 46 papers receiving a total of 396 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 12 papers in Epidemiology. Recurrent topics in Soon Hin How's work include Lung Cancer Treatments and Mutations (15 papers), Burkholderia infections and melioidosis (9 papers) and Lung Cancer Diagnosis and Treatment (8 papers). Soon Hin How is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Burkholderia infections and melioidosis (9 papers) and Lung Cancer Diagnosis and Treatment (8 papers). Soon Hin How collaborates with scholars based in Malaysia, United States and China. Soon Hin How's co-authors include Jamalludin Ab Rahman, Chong Kin Liam, Farah Al‐Marzooq, Lye Mun Tho, Rajesh Rajalingam, Pathmanathan Rajadurai, Yuanlin Song, Ki‐Suck Jung, Ji Young Park and Sunghoon Park and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and The Annals of Thoracic Surgery.

In The Last Decade

Soon Hin How

43 papers receiving 384 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Soon Hin How Malaysia 11 133 91 74 71 46 46 396
Erin E. Conners United States 12 311 2.3× 38 0.4× 93 1.3× 32 0.5× 49 1.1× 29 523
Ewelina Gowin Poland 10 105 0.8× 28 0.3× 71 1.0× 30 0.4× 20 0.4× 53 338
Tisungane Mvalo United States 13 131 1.0× 86 0.9× 126 1.7× 21 0.3× 18 0.4× 50 454
Stephen Mac Canada 11 119 0.9× 63 0.7× 46 0.6× 30 0.4× 45 1.0× 22 387
Sara Martin United States 8 160 1.2× 67 0.7× 66 0.9× 28 0.4× 24 0.5× 11 373
Rodrigo de Carvalho Santana Brazil 12 139 1.0× 22 0.2× 67 0.9× 27 0.4× 41 0.9× 39 440
Augustine Ebonyi Nigeria 12 101 0.8× 50 0.5× 261 3.5× 21 0.3× 20 0.4× 31 583
Inés Suárez‐García Spain 10 123 0.9× 35 0.4× 33 0.4× 18 0.3× 59 1.3× 34 411
Denise Schout Brazil 6 371 2.8× 82 0.9× 44 0.6× 20 0.3× 38 0.8× 9 523

Countries citing papers authored by Soon Hin How

Since Specialization
Citations

This map shows the geographic impact of Soon Hin How's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Soon Hin How with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Soon Hin How more than expected).

Fields of papers citing papers by Soon Hin How

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Soon Hin How. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Soon Hin How. The network helps show where Soon Hin How may publish in the future.

Co-authorship network of co-authors of Soon Hin How

This figure shows the co-authorship network connecting the top 25 collaborators of Soon Hin How. A scholar is included among the top collaborators of Soon Hin How based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Soon Hin How. Soon Hin How is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lim, Sun Min, Josiane Mourão Dias, Pei Jye Voon, et al.. (2024). Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.. Journal of Clinical Oncology. 42(17_suppl). LBA8612–LBA8612. 3 indexed citations
2.
Poh, Mau Ern, et al.. (2024). Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer. Translational Lung Cancer Research. 13(7). 1649–1659. 5 indexed citations
3.
Poh, Mau Ern, Chee-Shee Chai, Chong Kin Liam, et al.. (2024). Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?. Translational Lung Cancer Research. 13(2). 307–320. 2 indexed citations
4.
Poh, Mau Ern, Soon Hin How, Gwo Fuang Ho, et al.. (2023). Real-World Treatment and Outcomes of ALK-Positive Metastatic Non–Small Cell Lung Cancer in a Southeast Asian Country. Cancer Management and Research. Volume 15. 31–41. 2 indexed citations
5.
How, Soon Hin, et al.. (2022). Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?. Expert Review of Anticancer Therapy. 22(12). 1309–1323.
6.
How, Soon Hin, Chong Kin Liam, Lye Mun Tho, et al.. (2022). Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia. Cancer Management and Research. Volume 14. 1995–2005. 2 indexed citations
7.
How, Soon Hin, Lye Mun Tho, Chong Kin Liam, et al.. (2022). Programmed death‐ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non‐small‐cell lung cancer in a resource‐limited country. Thoracic Cancer. 13(11). 1676–1683. 3 indexed citations
8.
Wu, Yi‐Long, Christophe Dooms, Ernest Nadal, et al.. (2021). 1366TiP Tepotinib + osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2. Annals of Oncology. 32. S1036–S1036. 1 indexed citations
9.
Rajadurai, Pathmanathan, et al.. (2020). Lung Cancer in Malaysia. Journal of Thoracic Oncology. 15(3). 317–323. 24 indexed citations
10.
Liam, Chong Kin, Chee-Shee Chai, Gwo Fuang Ho, et al.. (2019). P2.14-47 Real-World Multicenter Experience of First-line Afatinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S848–S848. 1 indexed citations
11.
12.
How, Soon Hin, et al.. (2014). Monitoring treatment response in sputum smear positive pulmonary tuberculosis patients: comparison of weight gain, sputum conversion and chest radiograph.. PubMed. 36(2). 91–6. 9 indexed citations
13.
How, Soon Hin, et al.. (2012). Outbreak of melioidosis and leptospirosis co-infection following a rescue operation.. PubMed. 67(3). 293–7. 38 indexed citations
14.
How, Soon Hin, et al.. (2011). Intrapleural Streptokinase for the Treatment of Chylothorax. Respiratory Care. 56(12). 1953–1955. 4 indexed citations
15.
How, Soon Hin, et al.. (2011). Empyema Thoracis Complicated by Pneumothorax Necessitans Manifesting as Lobulated, Localized Subcutaneous Emphysematous Swellings. The Annals of Thoracic Surgery. 91(6). 1969–1971. 3 indexed citations
16.
How, Soon Hin, et al.. (2009). Hospitalised patients' awareness of their rights: a cross-sectional survey from a tertiary care hospital on the east coast of Peninsular Malaysia.. PubMed. 50(5). 494–9. 35 indexed citations
17.
Rahman, Jamalludin Ab, et al.. (2007). Perception of the Islamic ruling on smoking among Muslim adults in Malaysia; a preliminary survey. IIUM Medical Journal Malaysia. 6(2). 2 indexed citations
18.
How, Soon Hin, et al.. (2006). Endobronchial actinomycosis: is a repeat bronchoscopy after treatment necessary?. British Journal of Hospital Medicine. 67(1). 42–43. 1 indexed citations
19.
How, Soon Hin, et al.. (2006). Infective endocarditis in the East coast of peninsular Malaysia: a two year retrospective survey from Kuantan. The International Islamic University Malaysia Repository (The International Islamic University Malaysia). 13(1). 5–8. 2 indexed citations
20.
How, Soon Hin, et al.. (2006). Serum cancer antigen 125 in patients with pleural effusions.. PubMed. 61(5). 558–63. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erin E. Conners Breakdown of academic impact, for papers by Ewelina Gowin Breakdown of academic impact, for papers by Tisungane Mvalo Breakdown of academic impact, for papers by Stephen Mac Breakdown of academic impact, for papers by Sara Martin Breakdown of academic impact, for papers by Rodrigo de Carvalho Santana Breakdown of academic impact, for papers by Augustine Ebonyi Breakdown of academic impact, for papers by Inés Suárez‐García Breakdown of academic impact, for papers by Denise Schout
Rankless by CCL
2026